2026-525575-22-00
Recruiting
Phase 1
A first in human study of the safety, pharmacokinetics and pharmacodynamics of KLR-003 in healthy participants and patients with immune mediated diseases.
Klear Bio Inc.0 sites182 target enrollmentStarted: May 18, 2026Last updated:
Overview
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Klear Bio Inc.
- Enrollment
- 182
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Klear Bio Clinical Team
Scientific
Klear Bio Inc.
Similar Trials
Not yet recruiting
Phase 1
A trial to investigate the safety and pharmacokinetics of GRT6019 in healthy male participants.2025-523587-20-00Gruenenthal GmbH24
Not yet recruiting
Phase 1
To evaluate the pharmacokinetics and safety of nolasiban2025-523706-32-00ReproNovo ApS28
Recruiting
Phase 1
First in human clinical trial to evaluate the safety, tolerability and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer2022-503084-15-00Deutsches Krebsforschungszentrum (DKFZ)77
Active, not recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination with Palbociclib and/or LHRH Agonist in Patients with Locally Advanced or Metastatic Estrogen Receptor−Positive Breast Cancer2023-506700-12-00Genentech Inc.45
Recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients with Advanced or Metastatic Prostate Cancer2023-504013-68-00Genentech Inc.46